title: Bone marrow transplantation in Iran.
abstract: Seventy-three BMT procedures (42 allogeneic-BMT, 30 autologous-BMT, 1 syngeneic transplant) were undertaken at the Shariati Hospital in Tehran between March 1991 and November 1993. Allogeneic-BMT was performed for thalassaemia major (n = 23), AML in complete remission (n = 3), severe aplastic anaemia (n = 7), CML (n = 7), dyskeratosis congenita (n = 2) and Fanconi anaemia (n = 1). Conditioning regimens comprised busulphan (BU) plus cyclophosphamide (CY) or CY only. Thirty-two (78%) of the 43 patients remain alive 1-34 months after BMT. Twelve patients died: the causes of death were haemorrhagic cystitis (n = 1), CMV pneumonitis (n = 1), GVHD (n = 3), infection (n = 3), rejection (n = 1), VOD (n = 2) and hepatitis (n = 1). Autologous-BMT was performed for patients with AML in CR (n = 16), ALL in CR (n = 9), lymphoma in relapse (n = 3), Ewing sarcoma (n = 1) and multiple myeloma (n = 1). The median age was 18 years. Conditioning regimens were Ara C plus CY, etoposide plus CY and high-dose melphalan. Sixteen (54%) of the 30 patients survive, 14 in continuous complete remission. The causes of death were relapse (AML (n = 7), ALL (n = 4), lymphoma (n = 1)), VOD (n = 1) and infection (n = 1).
authors.affiliation: Dr Shariati Hospital, University of Medical Science, Tehran, Iran.
authors.forename: A
authors.initials: A
authors.lastname: Ghavamzadeh
authors.forename: M
authors.initials: M
authors.lastname: Jahani
authors.forename: E
authors.initials: E
authors.lastname: Baybordi
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000453:epidemiology / Q000628:therapy; D016026:Bone Marrow Transplantation / Q000191:economics; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005382:Financing, Personal; D006086:Graft vs Host Disease / Q000453:epidemiology; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007492:Iran / Q000453:epidemiology; D008223:Lymphoma / Q000453:epidemiology / Q000628:therapy; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D017086:beta-Thalassemia / Q000503:physiopathology / Q000628:therapy
chemical_list: D003561:Cytarabine; D003520:Cyclophosphamide; D002066:Busulfan; D008558:Melphalan